Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

June 18, 2020

Study Completion Date

January 3, 2023

Conditions
Advanced or Inoperable Gastric Cancer
Interventions
DRUG

Pamiparib

60 mg orally twice daily

DRUG

Placebo

60 mg orally twice daily

Trial Locations (65)

710

Chi Mei Medical Center, Tainan City

1122

Orszagos Onkologiai Intezet, Budapest

2250

Gosford Hospital, Gosford

3000

University Hospitals Leuven, Leuven

3168

Monash Health, Clayton

3355

Ballarat Oncology and Haematology Services, Wendouree

6008

St John of God Health Care, Subiaco

8000

Az Sint Jan Brugge, Bruges

18081

Fakultni Nemocnice Bulovka, Prague

22190

Hopital Prive Des Cotes Darmor Service Oncologie, Plérin

24298

Icm Val Daurelle Oncologie Medicale, Montpellier

25030

Chu Besancon Hopital Jean Minjoz, Doubs

28034

Hospital Universitario Ramon Y Cajal, Madrid

28050

Hospital Universitario Hm Madrid Sanchinarro, Madrid

28204

Novant Health Hematology Charlotte, Charlotte

28222

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda

29200

Chru de Brest Hospital Morvan, Brest

31008

Clinica Universidad de Navarra Pamplona, Pamplona

31059

Iuc Toulouse Oncopole, Toulouse

33176

Miami Cancer Institute, Miami

33401

Scri Florida Cancer Specialist East, West Palm Beach

35043

Centre Eugene Marquis, Rennes

40217

Norton Cancer Institute, Louisville

44805

Ico Site Rene Gauducheau, SaintHerblain

46010

Hospital Clinico Universitario de Valencia, Valencia

46526

Goshen Center For Cancer Care, Goshen

67214

Cancer Center of Kansas, Wichita

69008

Hopital Prive Jean Mermoz, Lyon

94805

Institut Gustave Roussy, Villejuif

97239

Oregon Health and Science University, Portland

100142

Beijing Cancer Hospital, Beijing

110042

Liaoning Cancer Hospital and Institute, Shenyang

163045

Arkhangelsk Regional Clinical Oncological Dispensary, Arkhangelsk

197022

Pavlov First Saint Petersburg State Medical University, SaintPetersburg

200032

Affiliated Zhongshan Hospital of Fudan University, Shanghai

210008

Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing

230000

Anhui Provincial Hospital, Hefei

250117

Shandong Cancer Hospital, Jinan

266000

The Affiliated Hospital of Qingdao University Branch South, Qingdao

305035

Regional Buz Kurskiy Regional Clinical Oncologic Dispensary, Kursk

308433

Tan Tock Seng Hospital Oncology, Singapore

400138

State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary, Volgograd

510060

Sun Yat Sen University Cancer Center, Guangzhou

510515

Nanfang Hospital of Southern Medical University, Guangzhou

515031

Cancer Hospital of Shantou University Medical College, Shantou

644013

Bih of Omsk Region Clinical Oncology Dispensary, Omsk

0112

Acad Fridon Todua Medical Center Ltd Research Institute of Clinical Medicine Ltd, Tbilisi

Unknown

Queen Mary Hospital, Hong Kong

H-7624

Pecsi Tudomanyegyetem Klinikai Kozpont, Pécs

811-1395

Nho Kyushu Cancer Center, Fukuoka

630-0293

Kindai University Nara Hospital, Ikoma

879-5593

Oita University Hospital, Yufushi

589-8511

Kindai University Hospital, Sayama

565-0871

Osaka University Hospital, Suitashi

350-1298

Saitama Medical University International Medical Center, Hidakashi

135-8577

Showa University Koto Toyosu Hospital Oncology, Koto

81-519

Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia, Gdynia

20-090

Centrum Onkologii Ziemi Lubelskiej, Lublin

02-034

Narodowy Instytut Onkologii Im Marii Skodowskiej Curie Pastwowy Instytut Badawczy, Warsaw

05-135

Mazowiecki Szpital Onkologiczny, Wieliszew

08025

Hospital de La Santa Creu I Sant Pau, Barcelona

08035

Hospital Universitario Vall Dhebron, Barcelona

08908

Institut Catala Doncologia, Barcelona

W1G 6AD

Sarah Cannon Research Institute Uk, London

CH63 4JY

Clatterbridge Cancer Centre, Metropolitan Borough of Wirral

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT03427814 - Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer | Biotech Hunter | Biotech Hunter